Influx Healthtech Ltd
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Influx Healthtech Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
IPO Snapshot
Key metrics and details at a glance.
Price Band
₹96
Per ShareLot Size
1200 Shares
Minimum Investment
₹1,15,200
Issue Size
₹58.57 Cr
Face Value
₹10
Per ShareIPO Type
Book Building - SME
Retail Quota
35%
QIB Quota
50%
NII Quota
15%
IPO Timeline
Important dates for your applying strategy.
Subscription Status
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
Influx Healthtech Ltd
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
99.85%
Promoter Holding (Post-Issue)
73.53%
Issue Type
Book Building - SME
ISIN
INE0MYZ01012
About the Company
Influx Healthtech Limited is a Mumbai-based, healthcare focused company specialising in contract manufacturing. Since its inception in 2020, the Company has established itself as a reliable Contract Development and Manufacturing Organization (CDMO), offering production of Dietary and Nutritional Supplements, Cosmetics, Ayurvedic/Herbal Products, Veterinary Feed Supplements, Homecare Products, Active Pharmaceutical Ingredients (APIs), and finished dosage forms, including tablets, capsules, and injectables.
Industry Overview
The company has established itself as a reliable Contract Development and Manufacturing Organization (CDMO), offering specialized services to a wide range of clients across various industries. The industry in which company operates are various products / SKUs under Dietary/Nutritional Supplement, Cosmetics, Ayurvedic / Herbal formulations, Veterinary Feed Supplements, Homecare segment /sector.
Company History
Influx Healthtech Limited was originally incorporated on September 28, 2020 as a Private Limited Company as "Influx Healthtech Private Limited" vide Registration No. 346825 under the provisions of the Companies Act, 2013 with the Registrar of Companies, Central Registration Centre. Pursuant to a special resolution passed by the Shareholders at their Extra ordinary General Meeting held on May 09, 2022, the Company was converted from a Private Limited Company to Public Limited Company and consequently, the name of the Company was changed to `Influx Healthtech Limited' and a Fresh Certificate of Incorporation consequent to Conversion was issued on May 23, 2022 by the Registrar of Companies, Mumbai. The Corporate Identification Number of the Company is U24299MH2020PLC346825.
Products & Services
- Influx Healthtech Limited is a Mumbai-based, healthcare focused company specialising in contract manufacturing.
Growth Strategy
- Grow its Nutraceutical and Veterinary Food Division and purchase machinery for the Homecare and Cosmetic Division
- Expansion of Manufacturing Facility for Nutraceutical Division.
- Exploring the Veterinary Food Division.
Customer Base
wholesaler and Retailer
Financial Performance
Revenue, profit after tax and total assets across the last 3 reported financial years.
Revenue
Amount in ₹ crore
Profit After Tax (PAT)
Amount in ₹ crore
Total Assets
Amount in ₹ crore
Figures in ₹ crore, on a standalone basis, as reported for FY23 to FY25.
Objects of the Issue
How the company plans to utilize IPO proceeds.
Use of Proceeds
The funds raised through this IPO will be used for:
Initial public offer of 61,00,800 equity shares of face value of Rs. 10/- each (the "Equity Shares") of Influx Heathtech Limited ("the Company" or "IHL" or "the Issuer") at an offer price of Rs. 96/- per equity share for cash, aggregating Rs. 58.57 crores ("Public Offer") comprising of a fresh offer of 50,00,400 equity shares aggregating to Rs. 48.00 crores (the "Fresh Offer") and an offer for sale of 11,00,400 equity shares by the promoter selling shareholder, Munir Abdul Ganee Chandniwala ("Offer for Sale") aggregating to Rs. 10.56 crores, (Hereinafter Refferd as "Promoter Selling Shareholder") out of which 3,06,000 equity shares of face value of Rs. 10/- each, at an offer price of Rs. 96/- per equity share for cash, aggregating Rs. 2.94 crores will be reserved for subscription by the market maker to the offer (the "Market Maker Reservation Portion"). The public offer less market maker reservation portion i.e. offer of 57,94,800 equity shares of face value of Rs. 10/- each, at an offer price of Rs. 96/- per equity share for cash, aggregating Rs. 55.63 crores is herein after referred to as the "Net Offer". The public offer and net offer will constitute 26.35 % and 25.03 % respectively of the post-offer paid-up equity share capital of the company.
*Subject to approvals and market conditions.
Strengths & Risks
Key competitive advantages and factors to consider before investing.
- Diverse client base with longstanding CDMO relationships.
- Well versed and equipped advanced manufacturing facilities with global accreditations.
- Large and rapidly growing R&D capabilities across our product portfolio.
- Experienced Promoter and management team with strong industry expertise and successful track record.
- Robust Quality Assurance & Control practices.
- The Company is reliant on the demand from the nutraceutical industry for a significant portion of its revenue. Any downturn in the nutraceutical industry or an inability to increase or effectively manage its sales could have an adverse impact on the Company's business and results of operations.
- Its existing manufacturing facility are concentrated in a single region i.e., Palghar, Thane, Maharashtra and the inability to operate and grow its business in this particular region may have an adverse effect on its business, financial condition, results of operations, cash flows and future business prospects.
- The Company is dependent on few numbers of customers for sales. Loss of any of this large customer may affect its revenues and profitability.
- The company has historically derived, and may continue to derive, a signification of its supply from top 10 Suppliers. Also, the Company has not entered into long-term agreements with these suppliers. In the event the company is unable to procure adequate amounts of raw materials, at competitive prices its business, results of operations and financial condition may be adversely affected.
- Too much Geographical concentration of its Business on specific location can impact the company Business.